Stanford Accelerated Recovery Trial (START)

Not Recruiting

Trial ID: NCT01067144

Purpose

The goal of this study is to determine whether administering Gabapentin prior to surgery affects duration of pain and opioid use post-surgery. The investigators aim to compare gabapentin to placebo in a prospective, randomized clinical trial in which patients will be followed post-surgery until pain resolves and opioid use ceases.

Official Title

Stanford Accelerated Recovery Trial (START)

Stanford Investigator(s)

Ian Carroll, MD, MS
Ian Carroll, MD, MS

Associate Professor of Anesthesiology, Perioperative and Pain Medicine (Adult Pain)

Peter Schmidt
Peter Schmidt

Clinical Assistant Professor, Anesthesiology, Perioperative and Pain Medicine

Eligibility


INCLUSION CRITERIA

   - Age 18 to 75

   - Undergoing a scheduled surgery

   - English speaking

   - Ability and willingness to complete questionnaires or use Palm Pilot

EXCLUSION CRITERIA

   - Known kidney disease

   - Currently receiving gabapentin or (pregabalin) lyrica already

   - Cognitive impairment

   - Previous history of excessive sedation or adverse reaction to gabapentin (not it was
   tried but ineffective for nerve pain)

   - Coexisting chronic pain > 4/10 disorder in area other than surgical target

   - Plan to move out of state

   - Condition that would in judgment of team member make patient likely to be lost to
   follow-up

   - Elevated suicidality

   - Known pregnancy

   - Current symptoms of ataxia, dizziness, or sedation

   - Narrow angle glaucoma

   - Severe respiratory insufficiency (ie, severe emphysema or chronic obstructive
   pulmonary disease)

   - History of gastric bypass surgery and obstructive sleep apnea requiring continuous
   positive airway pressure (CPAP)

Intervention(s):

drug: Gabapentin

drug: Lorazepam (active control)

drug: Placebo (inactive)

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
ccto-office@stanford.edu
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.